Arcutis Biotherapeutics, Inc.
NASDAQ:ARQTBiotechnology
-$0.51 today
- Market cap
- $3.49B
- Beta
- 1.52
- P/E (TTM)
- -1400.0
- EPS (TTM)
- -$0.02
Volume 0.84M
Average 1.61M
ARQT Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Arcutis Biotherapeutics, Inc.NASDAQ: ARQT
Short-term Investments · Q2 FY2026 · quarter ended Jun 2026
Short-term investments rises 73.1% from a year ago
Short-term investments stood at $204.43M at the end of Q2 FY2026, up 73.1% from a year earlier and up 8.0% from the prior quarter. Over 3 fiscal years it compounded at -20.6% a year.
Context
- Short-term investments amounted to 41.8% of total assets at the end of Q2 FY2026, up 8.3 pp from a year earlier.
- Short-term investments increased in 1 of the last 3 fiscal years.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +73.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 178.08M USD
- Year-over-year change
- +13.7%
- 4-year CAGR
- -11.5%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 178.08M | +13.7% |
| FY2024 | 2024-12-31 | 156.62M | -14.6% |
| FY2023 | 2023-12-31 | 183.46M | -48.5% |
| FY2022 | 2022-12-31 | 355.95M | +22.5% |
| FY2021 | 2021-12-31 | 290.61M | — |
Short-term Investments vs competitors
How ARQT compares with its peers on the latest reported figures
- ARQT's Jun 2026 short-term investments of $204.43M is the highest of the 6 companies compared; the peer median is $42.69M.
- Its year-over-year change of +73.1% is the 3rd highest of 5, against a peer median of +142.2%.
- Short-term investments amounts to 41.8% of total assets for ARQT, versus a peer median of 38.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $204.43M | +73.1% | -20.6% | 41.8% | |
EVMNEvommune, Inc. | Mar 2026 | $163.15M | +282.0% | — | 50.6% |
| Mar 2026 | $76.76M | +2.4% | -25.7% | 38.6% | |
| Mar 2026 | $42.69M | +355666.7% | -15.1% | 72.9% | |
TTRXTurn Therapeutics Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding ARQT) | $42.69M | +142.2% | -20.4% | 38.6% | |
Competitors are the stored peer set for ARQT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 97.99M | 53.64M | 88.4M | 71.34M | 42.91M |
| Short-term Investments | 290.61M | 355.95M | 183.46M | 156.62M | 178.08M |
| Net Receivables | 362K | 8.46M | 25.81M | 73.07M | 146.23M |
| Inventory | 0 | 7.51M | 13.13M | 14.53M | 22.63M |
| Other Current Assets | 7.66M | 4.46M | 9.53M | 8.82M | 9.79M |
| Total Current Assets | 402.77M | 437.41M | 330.43M | 335.82M | 411.23M |
| Property, Plant & Equipment (Net) | 5.3M | 4.6M | 3.9M | 2.99M | 5.51M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 7.19M | 6.44M | 9.48M | 14.81M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 78K | 78K | 596K | 596K | 1.42M |
| Total Non-current Assets | 5.38M | 11.87M | 10.93M | 13.07M | 21.74M |
| Total Assets | 408.15M | 449.27M | 341.37M | 348.89M | 432.97M |
| Account Payables | 7.35M | 8.83M | 11.99M | 14.22M | 12.53M |
| Short-term Debt | 433K | 0 | 0 | 0 | 1M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 16.41M | 14.32M | 19.07M | 20.75M | 116.31M |
| Total Current Liabilities | 33.33M | 37.81M | 46.67M | 81.01M | 129.84M |
| Long-term Debt | 72.35M | 197.77M | 201.8M | 107.2M | 5.27M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 25K | 0 | 849K | 570K | 108.39M |
| Total Non-current Liabilities | 77.15M | 201.89M | 206.03M | 110.34M | 113.66M |
| Total Liabilities | 110.48M | 239.69M | 252.7M | 191.35M | 243.49M |
| Common Stock | 5K | 6K | 9K | 12K | 12K |
| Retained Earnings | (408.31M) | (719.76M) | (981.9M) | (1.12B) | (1.14B) |
| Accumulated OCI | (255K) | (1.09M) | 4K | (7K) | (44K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 297.68M | 209.58M | 88.67M | 157.54M | 189.48M |
| Total Debt | 77.56M | 202.54M | 205.92M | 110.59M | 6.27M |
| Net Debt | (20.43M) | 148.9M | 117.52M | 39.25M | (36.64M) |
Arcutis Biotherapeutics, Inc.
NASDAQ:ARQT
Intrinsic Alpha fair value
Locked
Current Price
$27.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.